Secukinumab: In psoriasis and beyond
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behç...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of the Egyptian Women’s Dermatologic Society |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jewd.jewd_80_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behçet’s disease. This review will throw light on secukinumab’s utility in psoriasis, as well as other dermatologic conditions. |
|---|---|
| ISSN: | 2090-2565 |